Baxter International vs GE HealthCare
Side-by-side comparison of AI visibility scores, market position, and capabilities
Deerfield IL hospital medical technology (NYSE: BAX) at $10.636B 2024 revenue; Vantive kidney care sold to Carlyle $3.8B (Jan 2025), new CEO Andrew Hider (Sep 2025) competing with ICU Medical for IV solutions and infusion systems.
About
Baxter International Inc. is a Deerfield, Illinois-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BAX) as an S&P 500 component — providing hospitals, nursing homes, ambulatory surgery centers, and home healthcare settings with intravenous (IV) solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, advanced surgical equipment, and digital health solutions through approximately 38,000 employees worldwide. In fiscal year 2024, Baxter reported $10.636 billion in revenue from continuing operations with a market capitalization of approximately $15 billion. Baxter has undergone significant strategic transformation: divesting its kidney care business (Vantive) to Carlyle Group for $3.8 billion in January 2025 and its biopharma solutions business for $4.25 billion in 2023, sharpening focus on its three core segments — Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. In July 2025, Baxter appointed Andrew Hider as President and CEO (effective September 2025), bringing operational excellence expertise from his tenure as CEO of ATS (where he doubled revenues and tripled the stock price). Founded in 1931, Baxter introduced the first commercially prepared IV solutions and the first commercially-built kidney dialysis system.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
About
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
AI Visibility Head-to-Head
Key Details
Also Compare
Baxter International vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.